TCIM
ALNY icon

TIAA CREF Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

TIAA CREF Investment Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$19.5M Sell
208,284
-127,409
-38% -$10.7M 0.01% 718
2018
Q4 		$24.5M Sell
335,693
-86,365
-20% -$6.64M 0.02% 581
2018
Q3 		$36.9M Buy
422,058
+245,463
+139% +$24.7M 0.02% 528
2018
Q2 		$17.4M Sell
176,595
-7,068
-4% -$701K 0.01% 813
2018
Q1 		$21.9M Sell
183,663
-71,653
-28% -$9.24M 0.01% 721
2017
Q4 		$32.4M Buy
255,316
+148,280
+139% +$18.6M 0.02% 576
2017
Q3 		$12.6M Sell
107,036
-401,816
-79% -$34.3M 0.01% 1009
2017
Q2 		$40.6M Buy
508,852
+383,214
+305% +$24.5M 0.03% 501
2017
Q1 		$6.44M Sell
125,638
-9,848
-7% -$455K ﹤0.01% 1423
2016
Q4 		$5.07M Sell
135,486
-78,714
-37% -$3.3M ﹤0.01% 1594
2016
Q3 		$14.5K Buy
214,200
+21,783
+11% +$1.54M 0.01% 915
2016
Q2 		$10.7M Sell
192,417
-1,788
-0.9% -$113K 0.01% 1032
2016
Q1 		$12.2M Sell
194,205
-6,582
-3% -$438K 0.01% 942
2015
Q4 		$18.9M Sell
200,787
-21,107
-10% -$1.96M 0.01% 775
2015
Q3 		$17.8M Sell
221,894
-190,888
-46% -$21.2M 0.01% 772
2015
Q2 		$49.5M Buy
412,782
+273,824
+197% +$32.7M 0.04% 486
2015
Q1 		$14.5M Buy
138,958
+6,836
+5% +$693K 0.01% 926
2014
Q4 		$12.8M Buy
132,122
+20,181
+18% +$1.87M 0.01% 960
2014
Q3 		$8.74M Sell
111,941
-51,260
-31% -$3.31M 0.01% 1184
2014
Q2 		$10.3M Sell
163,201
-87,933
-35% -$5.23M 0.01% 1137
2014
Q1 		$16.9M Sell
251,134
-4,470
-2% -$346K 0.01% 849
2013
Q4 		$16.4M Sell
255,604
-384
-0.2% -$22.9K 0.01% 874
2013
Q3 		$16.4M Buy
255,988
+13,553
+6% +$676K 0.01% 842
2013
Q2 		$7.52M Buy
+242,435
New +$6.45M 0.01% 1223

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

TIAA CREF Investment Management's ALNY Position: Q1 2019 in Review

TIAA CREF Investment Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 38% in Q1 2019, selling an estimated $10.7M and leaving 208,284 shares worth $19.5M. The position accounts for 0.01% of the portfolio, ranked #718.

TIAA CREF Investment Management first reported a position in ALNY in Q2 2013 and has held it in 24 quarters since. The position peaked at $49.5M in Q2 2015. 291 funds tracked by Wall St. Rank hold ALNY as of Q1 2019.

  • TIAA CREF Investment Management held 208,284 shares of Alnylam Pharmaceuticals worth $19.5M as of Q1 2019.
  • TIAA CREF Investment Management sold 127,409 Alnylam Pharmaceuticals shares in Q1 2019, an estimated $10.7M.
  • Alnylam Pharmaceuticals made up 0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #718 holding.
  • TIAA CREF Investment Management first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 24 quarters since.
  • TIAA CREF Investment Management's Alnylam Pharmaceuticals position peaked at $49.5M in Q2 2015.
  • 291 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.